Switch theme
Sign up to access all valuation multiples
Navamedic ASA is a pharmaceutical company supplying hospitals and pharmacies with pharmaceutical and medical nutrition products. The company generates its revenue from the Nordic countries.
2002
45
LTM Revenue $52.9M
LTM EBITDA $3.8M
$46.2M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Navamedic has a last 12-month revenue of $52.9M and a last 12-month EBITDA of $3.8M.
In the most recent fiscal year, Navamedic achieved revenue of $51.2M and an EBITDA of $4.7M.
Navamedic expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Navamedic valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $49.4M | $51.2M | XXX | XXX | XXX |
| Gross Profit | $15.8M | $19.2M | XXX | XXX | XXX |
| Gross Margin | 32% | 37% | XXX | XXX | XXX |
| EBITDA | $2.9M | $4.7M | XXX | XXX | XXX |
| EBITDA Margin | 6% | 9% | XXX | XXX | XXX |
| Net Profit | $2.8M | $0.3M | XXX | XXX | XXX |
| Net Margin | 6% | 1% | XXX | XXX | XXX |
| Net Debt | $0.2M | $12.6M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 13, 2025, Navamedic's stock price is NOK 22 (or $2).
Navamedic has current market cap of NOK 392M (or $37.8M), and EV of NOK 480M (or $46.2M).
See Navamedic trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $46.2M | $37.8M | XXX | XXX | XXX | XXX | $-0.07 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 13, 2025, Navamedic has market cap of $37.8M and EV of $46.2M.
Navamedic's trades at 0.9x LTM EV/Revenue multiple, and 12.3x LTM EBITDA.
Analysts estimate Navamedic's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Navamedic and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $46.2M | XXX | XXX | XXX |
| EV/Revenue | 0.9x | XXX | XXX | XXX |
| EV/EBITDA | 9.8x | XXX | XXX | XXX |
| P/E | -71.5x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 13.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialNavamedic's NTM/LTM revenue growth is 11%
Navamedic's revenue per employee for the last fiscal year averaged $1.1M, while opex per employee averaged n/a for the same period.
Over next 12 months, Navamedic's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Navamedic's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Navamedic and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 4% | XXX | XXX | XXX | XXX |
| EBITDA Margin | N/A | XXX | XXX | XXX | XXX |
| EBITDA Growth | 60% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 0% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $1.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 0% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 0% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Ansell | XXX | XXX | XXX | XXX | XXX | XXX |
| Polymed | XXX | XXX | XXX | XXX | XXX | XXX |
| Farmaceutica Remedia | XXX | XXX | XXX | XXX | XXX | XXX |
| Etropal | XXX | XXX | XXX | XXX | XXX | XXX |
| Sopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Navamedic acquired XXX companies to date.
Last acquisition by Navamedic was XXXXXXXX, XXXXX XXXXX XXXXXX . Navamedic acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Navamedic founded? | Navamedic was founded in 2002. |
| Where is Navamedic headquartered? | Navamedic is headquartered in Norway. |
| How many employees does Navamedic have? | As of today, Navamedic has 45 employees. |
| Is Navamedic publicy listed? | Yes, Navamedic is a public company listed on OSL. |
| What is the stock symbol of Navamedic? | Navamedic trades under NAVA ticker. |
| When did Navamedic go public? | Navamedic went public in 2006. |
| Who are competitors of Navamedic? | Similar companies to Navamedic include e.g. Ansell, Polymed, Farmaceutica Remedia, Etropal. |
| What is the current market cap of Navamedic? | Navamedic's current market cap is $37.8M |
| What is the current revenue of Navamedic? | Navamedic's last 12-month revenue is $52.9M. |
| What is the current EBITDA of Navamedic? | Navamedic's last 12-month EBITDA is $3.8M. |
| What is the current EV/Revenue multiple of Navamedic? | Current revenue multiple of Navamedic is 0.9x. |
| What is the current EV/EBITDA multiple of Navamedic? | Current EBITDA multiple of Navamedic is 12.3x. |
| What is the current revenue growth of Navamedic? | Navamedic revenue growth between 2023 and 2024 was 4%. |
| Is Navamedic profitable? | Yes, Navamedic is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
